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CLINICAL, BIOCHEMICAL, ENDOSCOPIC, AND HISTOPATHOLOGICAL
EVALUATION OF THE BIOLOGICAL TREATMENT OF
ULCERATIVE COLITIS
EVALUACIÓN CLÍNICA, BIOQUÍMICA, ENDOSCÓPICA E HISTOPATOLÓGICA DEL TRATAMIENTO
BIOLÓGICO DE COLITIS ULCERATIVA
Carlos Alberto López-Bernal1,a, Arturo García-Galicia1,b,f, Francisco Javier Quezada-Juárez 2,c, Moisés Freddy Rojas-Illanes 3,a,
Briseida Rubio-Martínez 4,a, Álvaro José Montiel-Jarquín1,c,f, Ingrid Jiménez-Luna1,d, Jorge Loria-Castellanos 5,e

ABSTRACT
Introduction: Biological treatment is currently used as an alternative for the treatment of ulcerative colitis in patient's refractory to
conventional treatment. Objective: To evaluate biological treatment in patients with ulcerative colitis refractory to conventional
treatment in a 3rd level care Hospital. Methods: A descriptive, retrospective, longitudinal study was carried out in patients with UC
who were refractory to conventional treatment and who received biological treatment. The variables were evaluated in 3 moments:
basal state (without biological treatment), at six and twelve months from the start of biological treatment. Descriptive statistics
were used to characterize general population, later the 3 states mentioned above were described with their respective variables.
Results: Eighteen patients with a mean age of 41.2 years were included. Evaluations at baseline and at 6 and 12 months showed:
presence of blood in stools and abdominal pain in 94.4%%, 22.2% and 11.1% respectively; hemoglobin concentration >10.5 g/dl in
50%, 83.3% and 88.9%; serum albumin concentration >3.2 g/dl in 72.2%, 83.3% and 88.9%; the visual Mayo endoscopic scale 38.9%,
33.3% and 16.7% presented Mayo 2 and 61.1%, 16.7% and 1.7% Mayo 3. The histological activity in the baseline evaluation reached
a severe level (11.1%), while in evaluations at 6 and 12 months they reached moderate in 55.6% and 27.8% respectively.
Conclusions: Biological therapy as a treatment in patients with ulcerative colitis showed improvement in clinical, biochemical,
endoscopic and histological manifestations, so far none with deep remission of the disease, no adverse reactions to treatment have
been presented.
Keywords: Colitis, Ulcerative; Treatment; Biological; Endoscopic; Clinical. (Source: MESH-NLM)

RESUMEN
Introducción: El tratamiento biológico es una alternativa para manejar la colitis ulcerativa en pacientes refractarios al tratamiento
convencional. Objetivo: Evaluar el tratamiento biológico en pacientes con colitis ulcerativa refractarios al tratamiento
convencional en un hospital de 3er nivel de atención. Métodos: Estudio descriptivo, retrospectivo, longitudinal en pacientes con
colitis ulcerativa refractarios al tratamiento convencional y que recibieron tratamiento biológico. Las cortes se evaluaron en tres
momentos: estado basal (sin terapia biológica), a los seis y doce meses de inicio del tratamiento biológico. Se utilizó estadística
descriptiva para la caracterización de la población en general, posteriormente los tres puntos de corte se describieron con sus
respectivas variables. Resultados: Se incluyeron 18 pacientes con edad media de 41,2 años. Las evaluaciones, en un estado basal, a
los seis y 12 meses; demostraron presencia de sangre en las evacuaciones y dolor abdominal en 94,4%, 22,2% y 11,1%
respectivamente, concentración de hemoglobina >10,5 g/dl en 50%, 83,3% y 88,9%; concentración sérica de albúmina >3,2 g/dl en
72,2%, 83,3% y 88,9% y escala visual endoscópica de Mayo 38,9%, 33,3% y 16,7% presentaron Mayo 2 y 61,1%, 16,7% y 1,7% Mayo 3.
La actividad histológica en la evaluación basal llego hasta un nivel severo (11,1%), mientras que en evaluaciones a seis y 12 meses
llegaron hasta moderada en un 55,6% y 27,8% respectivamente. Conclusiones: La terapia biológica en pacientes con colitis
ulcerativa refractaria demostró mejoría en manifestaciones clínicas, bioquímicas, endoscópicas e histológicas. No se registró
remisión profunda de la enfermedad, ni reacciones adversas al tratamiento.
Palabras clave: Colitis Ulcerosa; Tratamiento; Biológico; Endoscópica; Clínica. (Fuente: DeCS- BIREME)
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INTRODUCTION
Ulcerative colitis (UC) is chronic, nonspeci c
in ammation of the intestine characterized by periods
of disease activity and remission. Its diagnosis is based
on a series of clinical, endoscopic and histological
criteria (1) . UC usually predominates in adult patients
between 30 and 40 years of age (2) . In Mexico, the mean
number of new UC cases increased from 28.8 from 1987
to 1996 to 76.1 from 1997 to 2006(3) . The incidence and
prevalence have similar behavior in the rest of the world
(4)
. Presentation and development are aﬀected by
environmental changes (5) . The main goal of treatment
was to induce and maintain long-term remission.
According to the Montreal scale, mild, moderate, or
severe activity determines the treatment (6-9) .
Treatment for mild activity is the use of 5-aminosalicylic
acid (5-ASA)( 1 0 ) , adding steroids (for example,
prednisone 40-60 mg per day), or equivalent in case of
resistance (11) . In moderate activity, it is recommended
to add thiopurines (azathioprine or mercaptopurine) to
the treatment, which can also be used in steroiddependent patients (12) . For severe activity, biological
therapy is used (adalimumab, in iximab, among
others), and recently the Janus kinase inhibitor (JAK) for
rescue. Treatment with intravenous steroids or
cyclosporine is usually started for remission induction.
This therapy aims to maintain the remission of the
disease (13-15) . The use of in iximab with azathioprine has
a better response in steroid-dependent patients,
achieving remission after 16 weeks of treatment (16,17) .
Surgical treatment is reserved for emergencies or the
presence of premalignant and malignant lesions (18,19) .
The use of biological therapy has been proposed in
cases of resistance to primary treatment (19) , but the
information is still scarce. So far, there are no predictors
of the real behavior of the disease, which help improve
treatment and even prevention. Neither is the study of
management in case of persistence despite treatment.
Hence the importance of evaluating the response to
biological therapy, given the lack of long-term studies.
The objective of this study was to evaluate the results of
the biological treatment at 12 months in patients with
UC refractory to conventional treatment in the
Coloproctology Service of a tertiary care hospital in
Mexico City, Mexico.
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METHODS
Design and study area
A descriptive, retrospective, longitudinal study was
carried out in patients with UC who were refractory to
conventional treatment and who received biological
treatment in the Coloproctology Service of a tertiary
care hospital.

Population and sample
The records of patients diagnosed with UC in the
Coloproctology Service were reviewed. Identi ed cases
with a con rmed diagnosis of UC, who were under
biological therapy (adalimumab or in iximab) for 12
months, previously refractory to conventional
treatment (mesalazine, azathioprine, and steroids), of
any sex and age, who had endoscopic follow-up were
included. , biochemical, clinical, and histopathological.

Variables and instruments
The results of the evaluations were recorded: baseline,
six and 12 months after the start of biological therapy, of
clinical, biochemical, endoscopic, and histological
manifestations. After the baseline evaluation, biological
therapy with tumor necrosis factor inhibitors (anti-TNF)
such as in iximab or adalimumab was started.
Azathioprine or 5-ASA was used as a compliment.
Information was collected on: age, gender, height,
weight, body mass index (BMI), history of diabetes
mellitus and arterial hypertension, time of illness,
smoking, alcoholism, and appendectomy. Clinical
characteristics include bowel movements per day,
presence of mucus and blood in stool, abdominal pain,
extraintestinal manifestations (arthralgia, myalgia,
uveitis, and cirrhosis), and admission to the hospital for
associated complications were recorded at each
evaluation. The biochemical characteristics recorded
were serum hemoglobin, albumin and C-reactive
protein (CRP), and erythrocyte sedimentation rate
(ESR). Endoscopically, the rating was evaluated
according to the Mayo endoscopic scale and the degree
of histopathological activity.
The following scales were applied:
-Disease activity was measured, with nine clinical and
biochemical characteristics: number of bowel
movements per day, blood in stool, fever, tachycardia,
hemoglobin, ESR, total leukocytes, serum albumin, and
potassium(20,21) .
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of central tendency and dispersion were used for the
quantitative variables. The statistical program SPSS
version 25.0 from IBM was used.

-The Mayo endoscopic scale for UC evaluates its activity
through the frequency of bowel movements, bleeding
characteristics, endoscopic ndings of the mucosa and
medical assessment. The activity is divided into 0)
normal, mucosa without lesions or in an inactive phase;
1) mild, mild erythema, decreased vascular pattern,
mild friability; 2) moderate, marked erythema, absence
of vascular pattern, friability, punctate erosions or
ulcers; and 3) intense, spontaneous bleeding and
ulcerations (7,21,22) .

Ethical aspects
The present study complied with the ethical principles
for the incorporation of patients in the study, handling
personal data with strict con dentiality. All patients
signed an informed consent letter when applying the
quality of life scale. The protocol was approved by the
Health Research Committee No. 3 601 of the Mexican
Institute of Social Security, with registration number R2020-3601-090.

-Histologic activity for UC is classi ed as no activity, mild
activity, moderate activity, and severe activity. It is
reported according to the anatomopathological study.

RESULTS

-All patients are questioned about symptoms added to
UC. The records were intentionally searched for any
clinical condition related or not to the application of the
medications.

Eighteen patients were included with a mean age of
41.2 (±11.8) years, ten (55.6%) women and eight (44.4%)
men. The mean height was 1.61 (±0.8) meters, the mean
weight 66.6 (±13.8) kilograms, and the mean BMI was
24.2 (±4) kg/m2. No history of diabetes mellitus or
hypertension was found in the population evaluated. A
history of smoking was present in two (11.1%) patients,
regular alcohol consumption in six (33.3%) patients,
and appendectomy in three (16.7%) patients.

Procedures
The biological treatment consisted of administering
In iximab or Adalilumab according to the following
schemes:
-The administration of In iximab is at zero, two and six
weeks and subsequently every eight weeks at a dose of
ve to ten mg/kg intravenously.
-Adalimumab was administered at doses of 160/80 mg
or 80/40 mg subcutaneously every two weeks 23,24.
-Azathioprine was applied at 2.5-3 mg/kg/day 25.

Baseline evaluation
It was observed that the 18 patients presented more
than six evacuations per day, 18 reported mucus in
evacuations, and 17 registered hematochezia and
abdominal pain. In addition, 11 patients presented
extraintestinal activity (arthralgia, myalgia, uveitis, and
cirrhosis) (Figure 1).

Statistical analysis
It was performed using descriptive statistics. Measures

Moco en evacuaciones

Dolor abdominal

Ac vidad extraintes nal

Sangre en evacuaciones

ESTADO BASAL

61.10%

61.10%
6 MESES

11.10%

5.50%

11.10%

11.10%

38.80%

22.20%

5.50%

38.80%

61.10%

94.40%

>6 evacuaciones/día

94.40%

100%

100%

Caracterís cas clínicas

12 MESES

Figure 1. Clinical characteristics of the patients.
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Serum hemoglobin greater than 10.5 g/dl was recorded
in 50% of patients, serum albumin greater than 3.2 g/dl

dl in 72.2%, ESR more signi cant than 10 mm/h in
94.4%, and CRP less than 10 mg/dl in 88.9% (Figure 2).

CARACTERÍSTICAS BIOQUÍMICAS
PCR <10 mg/dl

100%

83.30%

88.80%

77.70%

VSG <10 mm/h

27.70%

6 MESES

12 MESES

5.50%

27.70%

50%

72.20%

83.30%

Albumina sérica>3.2 gr/dl

83.30%

88.80%

Hemoglobina sérica >10.5 mg/dl

ESTADO BASAL

ESR=Erythrocyte sedimentation rate. CRP= C-reactive protein

Figure 2. Biochemical characteristics of the patients.
En la escala visual endoscópica de Mayo para CU, 11(61,1%) pacientes presentaron un nivel de Mayo 3 (Figura 3).

55.6%

ESTADO BASAL

6 MESES

Mayo 0

Mayo 1

Mayo 2

16.7%

16.7%

11.1%

5.6%

0%

0%

16.7%

33.3%

38.9%

44.4%

61.1%

Comportamiento endoscópico
(Escala endoscópica Mayo)

12 MESES

Mayo 3

Figure 3. Endoscopic behavior of patients.
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The most frequent degree of histological activity was moderate activity in 15 (83.3%) people (Figure 4).

27.8%

ESTADO BASAL

0%

11.1%
0%

11.1%

11.1%

5.6%

0%

33.3%

55.6%

61.1%

83.3%

Ac vidad histológica

6 MESES

Ausente

Leve

Moderada

12 MESES

Severa

Figure 4. The histological activity of the patients.
Regarding hospitalizations, 13 (72.2%) patients did not

In the endoscopic visual scale, a higher frequency of

require hospital management and 5 (27.8%) patients

Mayo level 1 was found in 8 (44.4%) patients (Figure 3).

required hospital care before starting the biological

The histological activity was moderate in 10 (55.6%)

treatment. 100% of the patients were refractory to

patients (Figure 4).

conventional combined treatment to control the
disease before starting the biological treatment. After

Evaluation 12 months after starting the

the baseline evaluation, biological therapy with anti-

biologic

Tumor Necrosis Factor agents such as In iximab was

We found 16 patients with less than six bowel

started in 10 (55.6%) patients and Adalimumab in 8

movements per day, two patients with mucus in bowel

(44.4%) patients. Azathioprine was supplemented in

movements, one patient with blood in bowel

50% of the patients and 5-ASA in 83.3%.

movements, and two patients with abdominal pain. The
extraintestinal activity was present in 11 patients

Six-month evaluation

(Figure 1). Hemoglobin concentration was >10.5 g/dl in

Clinically, 17 patients had fewer than six stools per day;

16 (88.9%) patients, and serum albumin concentration

seven had mucus-containing stools, four had blood in

>3.2 g/dl was found in 18 (88.9%) patients. ESR was

the stools, and seven had abdominal pain. Regarding

greater than 10 mm/h in 13 (72.2%) patients, and CRP

extraintestinal activity, it was present in 11 patients

<10 mg/dl in 15 (83.3%) patients (Figure 2).

(Figure 1).
In the Mayo visual endoscopic scale for UC, in 10 (55.6%)
A hemoglobin concentration >10.5 g/dl was found in 15

patients, it was Mayo 1 (Figure 3). The mild histological

(83.3%) patients; serum albumin concentration was

activity was found in 11 (61.1%) patients (Figure 4). No

>3.2 g/dl in 15 (83.3%) patients. ESR was <10 mm/h in 5

clinical symptomatology other than the initial UC

(27.8%) patients, and CRP <10 mg/dl was found in 14

symptoms that appeared related to the application of

(77.8%) patients (Figure 2).

the drugs was recorded up to 72 hours after them.
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DISCUSSION
Biological therapy has demonstrated eﬃcacy and
safety in UC, achieving clinical, endoscopic, histological,
and biochemical remission (13,15) . In the follow-up of
patients, once the diagnosis is made and treatment
started, endoscopic control is recommended at three to
six months; clinically, they should be evaluated every
three months; once remission is achieved, surveillance
can be every six to twelve months (26) . The present work
was carried out through a basal state and two cuts at six
and twelve months, analyzing four aspects: clinical,
biochemical, endoscopic and histological.

is also observed at six and 12 months in relation to
conventional therapy, also adding to the perception of
the quality of life of our patients. Adalimumab induces
and maintains remission in 40 to 59.9% of patients with
moderate to severe activity in a follow-up of four years
(29,30)
. The response with adalimumab in this study was
similar to that observed with in iximab, a therapy
combo. Follow-up was recorded at 12 months and is
currently continuing.
The immediate adverse reactions associated with the
use of in iximab and adalimumab are very similar. They
include pruritus, edema, urticaria, hypotension or

The histological cure is the complete remission of UC
and is associated with a reduc tion in future
complications in clinical practice. In this study, an
adequate histological response was obtained, and one
patient achieved complete histological remission but
not deep remission, which consists in the absence of
clinical, endoscopic, histological and biochemical
activity.
In iximab therapy is considered the rst line of
treatment for UC refractory to conventional treatment
and severe activity. It induces and maintains remission
up to 52 weeks after its onset (27) . In iximab treatment
slightly predominated in this study. Most of the patients
registered sustained response, which consists of the
absence of relapses during treatment therapy was used
combo, which consists of the use of the biological
(In iximab/Adalimumab), added the use of an
azathioprine-type immunomodulator. In iximab
shows an 80% advantage over placebo in a ve-year,
with a 50% reduction in the risk of colectomy in patients
with severe ulcerative colitis (28) . In the present study, a
superior response to biological therapy with in iximab

hypertension, bradycardia or tachycardia, headaches,
fever, and anaphylactic shock. Arthralgias, myalgias,
urticaria, rashes, fever, or headaches may occur (21) hours
after administration. Adverse eﬀects associated with
azathioprine are fever, arthralgia, skin rash, malaise,
nausea, acute pancreatitis, leukopenia,
thrombocytopenia, anemia, infections, and in some
cases, hepatitis or tumors (22) . No adverse eﬀects were
recorded in the present study. This argues in favor of the
safety of the drug regimens used. However, its
presentation can occur in larger samples.
A comparison of a formal assessment of the quality of
life before and after the start of biological therapy is
necessary for more robust conclusions. Expanding the
sample and longer-term follow-up is also desirable to
show the diﬀerences between both treatments. In
conclusion, the clinical, endoscopic, biochemical, and
histological response in patients who were refractory to
conventional treatment was satisfactory. None of them
have presented adverse events, nor have patients been
hospitalized.
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